Analysts Set Chemours Co (CC) Price Target at $48.14

Chemours Co (NYSE:CC) has received an average recommendation of “Buy” from the eleven research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $48.14.

CC has been the subject of several analyst reports. SunTrust Banks raised shares of Chemours from a “hold” rating to a “buy” rating and raised their price target for the company from $40.00 to $52.00 in a report on Monday. ValuEngine raised shares of Chemours from a “strong sell” rating to a “sell” rating in a report on Wednesday, February 20th. Citigroup reissued a “buy” rating and issued a $43.00 price target on shares of Chemours in a report on Wednesday, February 20th. Barclays reissued a “buy” rating and issued a $48.00 price target on shares of Chemours in a report on Tuesday, January 15th. Finally, Zacks Investment Research downgraded shares of Chemours from a “hold” rating to a “sell” rating in a research note on Friday, January 4th.

Chemours stock opened at $39.29 on Tuesday. Chemours has a 1-year low of $25.17 and a 1-year high of $53.25. The company has a market capitalization of $6.53 billion, a P/E ratio of 6.93, a price-to-earnings-growth ratio of 0.57 and a beta of 2.29. The company has a quick ratio of 1.26, a current ratio of 1.93 and a debt-to-equity ratio of 3.88.

Chemours (NYSE:CC) last released its quarterly earnings data on Thursday, February 14th. The specialty chemicals company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.04 by $0.01. Chemours had a net margin of 14.99% and a return on equity of 98.83%. The business had revenue of $1.46 billion during the quarter, compared to analyst estimates of $1.53 billion. During the same period in the previous year, the business earned $1.19 EPS. Chemours’s revenue was down 7.0% compared to the same quarter last year. Sell-side analysts forecast that Chemours will post 4.58 EPS for the current year.

In other Chemours news, VP Amy Trojanowski sold 13,536 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $38.63, for a total value of $522,895.68. Following the transaction, the vice president now owns 54,367 shares in the company, valued at $2,100,197.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Paul Kirsch sold 10,000 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $38.66, for a total transaction of $386,600.00. The disclosure for this sale can be found here. Insiders sold 101,924 shares of company stock worth $3,924,730 in the last 90 days. Corporate insiders own 2.34% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in CC. Financial Architects Inc lifted its stake in shares of Chemours by 39.2% in the fourth quarter. Financial Architects Inc now owns 1,421 shares of the specialty chemicals company’s stock worth $40,000 after buying an additional 400 shares in the last quarter. Lavaca Capital LLC bought a new position in shares of Chemours in the fourth quarter worth approximately $44,000. Country Trust Bank bought a new position in shares of Chemours in the first quarter worth approximately $51,000. TCI Wealth Advisors Inc. lifted its stake in shares of Chemours by 27.5% in the first quarter. TCI Wealth Advisors Inc. now owns 1,916 shares of the specialty chemicals company’s stock worth $71,000 after buying an additional 413 shares in the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co lifted its stake in shares of Chemours by 357.1% in the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 3,200 shares of the specialty chemicals company’s stock worth $90,000 after buying an additional 2,500 shares in the last quarter. Institutional investors own 80.94% of the company’s stock.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging.

Further Reading: What are gap-down stocks?

Analyst Recommendations for Chemours (NYSE:CC)

Receive News & Ratings for Chemours Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours and related companies with MarketBeat.com's FREE daily email newsletter.